Lite Strategy

Lite Strategy FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Lite Strategy (LITS) as of Nov 20, 2026 is 12.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 130.72 % — a change of -90.19% (lower).

FCF Conversion

12.82 %

YoY

-90.19%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Lite Strategy is 2026 12.82 % . FCF Conversion Rate (FCF/EBITDA) of Lite Strategy was 2025 130.72 % . It decreases by -90.19% lower compared to the previous year.

The Lite Strategy FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
176.22 USD
Jan 1, 2020
-70.74 USD
Jan 1, 2021
79.08 USD
Jan 1, 2022
90.40 USD
Jan 1, 2023
164.96 USD
Jan 1, 2024
-283.95 USD
Jan 1, 2025
130.72 USD
Jan 1, 2026
12.82 USD
The Lite Strategy FCF Conversion history
YEARFCF ConversionYoY
12.82 %-90.19%
130.72 %-146.04%
-283.95 %-272.13%
164.96 %+82.48%
90.40 %+14.31%
79.08 %-211.79%
-70.74 %-140.15%
176.22 %+231.51%
53.16 %-58.74%
128.84 %+50.48%
85.62 %-0.36%
85.93 %+19.64%
71.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

FCF Conversion Rate (FCF/EBITDA) of Lite Strategy is 12.82 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Lite Strategy changed from 130.72 % to 12.82 %, representing a -90.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Lite Strategy with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Lite Strategy

All Key Metrics — Lite Strategy